Julia Louza1, Eike Krause1, Robert Gürkov1. 1. Department of Otorhinolaryngology-Head and Neck Surgery, Ludwig-Maximilians-University of Munich, Munich, Germany.
Abstract
OBJECTIVES/HYPOTHESIS: The aim of this study was to evaluate the long-term influence of intratympanic gadolinium-based contrast agent on hearing function in patients with possible Ménière's disease and normal auditory thresholds who were undergoing locally enhanced magnetic resonance imaging scans. STUDY DESIGN: Prospective observational cohort study in a tertiary referral university hospital ear, nose, and throat department. METHODS: Between 2009 and 2012, 17 patients with possible or probable Ménière's disease and a four-tone pure-tone average baseline of <25 dB were recruited for our study. Before undergoing intratympanic injection of gadolinium-based contrast agent, all patients underwent a complete audiological evaluation. The study population was then invited back after at least 6 months postinjection for a follow-up auditory evaluation. This consisted of comprehensive clinical and audiological tests on both sides and were evaluated according to the ototoxicity guidelines. RESULTS: A long-term evaluation of our study group revealed no significant difference in the air-conduction pure-tone average. Furthermore, no statistical difference at individual frequencies compared to baseline was found. There was no evidence of ototoxicity in the injected ear. CONCLUSIONS: Long-term hearing function assessment after intratympanic application of gadolinium-based agent showed no evidence of ototoxicity. The use of intratympanic gadolinium-based agent in the diagnosis of Ménièrés disease is currently a helpful tool, and seems to be a safe method, especially with regard to auditory function. LEVEL OF EVIDENCE: 4.
OBJECTIVES/HYPOTHESIS: The aim of this study was to evaluate the long-term influence of intratympanic gadolinium-based contrast agent on hearing function in patients with possible Ménière's disease and normal auditory thresholds who were undergoing locally enhanced magnetic resonance imaging scans. STUDY DESIGN: Prospective observational cohort study in a tertiary referral university hospital ear, nose, and throat department. METHODS: Between 2009 and 2012, 17 patients with possible or probable Ménière's disease and a four-tone pure-tone average baseline of <25 dB were recruited for our study. Before undergoing intratympanic injection of gadolinium-based contrast agent, all patients underwent a complete audiological evaluation. The study population was then invited back after at least 6 months postinjection for a follow-up auditory evaluation. This consisted of comprehensive clinical and audiological tests on both sides and were evaluated according to the ototoxicity guidelines. RESULTS: A long-term evaluation of our study group revealed no significant difference in the air-conduction pure-tone average. Furthermore, no statistical difference at individual frequencies compared to baseline was found. There was no evidence of ototoxicity in the injected ear. CONCLUSIONS: Long-term hearing function assessment after intratympanic application of gadolinium-based agent showed no evidence of ototoxicity. The use of intratympanic gadolinium-based agent in the diagnosis of Ménièrés disease is currently a helpful tool, and seems to be a safe method, especially with regard to auditory function. LEVEL OF EVIDENCE: 4.
Authors: Yew Song Cheng; Elliott D Kozin; Aaron K Remenschneider; Hideko Heidi Nakajima; Daniel J Lee Journal: Otol Neurotol Date: 2016-01 Impact factor: 2.311
Authors: Marc van Hoof; Raymond van de Berg; Marly F J A van der Lubbe; Akshayaa Vaidyanathan; Marjolein de Wit; Elske L van den Burg; Alida A Postma; Tjasse D Bruintjes; Monique A L Bilderbeek-Beckers; Patrick F M Dammeijer; Stephanie Vanden Bossche; Vincent Van Rompaey; Philippe Lambin Journal: Radiol Med Date: 2021-11-25 Impact factor: 3.469
Authors: Marly F J A van der Lubbe; Akshayaa Vaidyanathan; Vincent Van Rompaey; Alida A Postma; Tjasse D Bruintjes; Dorien M Kimenai; Philippe Lambin; Marc van Hoof; Raymond van de Berg Journal: J Neurol Date: 2020-11-17 Impact factor: 4.849